晚期非小细胞肺癌免疫治疗持续时间与总生存的关联
这项回顾性、基于人群的队列研究纳入2016至2020年确诊并接受一线免疫治疗的晚期非小细胞肺癌成人患者,比较2年固定期限停药与超过2年持续治疗的总生存。在760天时仍无进展且继续免疫治疗的1091例患者中,约五分之一在2年时停药;固定期限组与持续治疗组从760天起的2年总生存率分别为79%和81%,单变量和多变量分析均无统计学显著差异。
要点
- 在2年时无进展且仍在免疫治疗的患者中,约五分之一在2年时停药。
- 固定期限组从760天起的2年总生存率为79%,持续治疗组为81%。
- 调整混杂因素后,固定期限组与持续治疗组的总生存无统计学显著差异。
核心结论
- 在2年时无进展的晚期非小细胞肺癌免疫治疗患者中,仅约五分之一在2年时停药。
- 调整分析未显示持续治疗组具有统计学显著的总生存优势,这为希望在2年时停止免疫治疗的患者和临床医生提供了安慰。
研究设计与样本
- 这项回顾性、基于人群的队列研究纳入临床数据库中2016至2020年确诊的晚期非小细胞肺癌成人患者,均接受一线免疫治疗。
- 数据截止日期为2022年8月31日;数据分析于2022年10月至2023年1月进行。
- 暴露分为2年时停药(700至760天之间,固定期限)与超过2年持续治疗(大于760天,无限期)。
- 分析队列为排除死亡和进展后、在免疫治疗2年时仍在治疗的1091例患者。
主要发现
- 固定期限组113例,中位(IQR)年龄69(62-75)岁,女性62例(54.9%),白人86例(76.1%)。
- 持续治疗组593例,中位(IQR)年龄69(62-76)岁,女性282例(47.6%),白人414例(69.8%)。
- 固定期限组有吸烟史者比例更高(99% vs 93%;P = .01),在学术中心接受治疗者比例更高(22% vs 11%;P = .001)。
- 从760天起的2年总生存率,固定期限组为79%(95% CI,66%-87%),持续治疗组为81%(95% CI,77%-85%)。
- 单变量Cox回归中,固定期限组与持续治疗组的总生存无统计学显著差异(HR 1.26;95% CI,0.77-2.08;P = .36);多变量Cox回归中亦无统计学显著差异(HR 1.33;95% CI,0.78-2.25;P = .29)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: For patients with advanced non-small cell lung cancer (NSCLC) treated with frontline immunotherapy-based treatment, the optimal duration of immune checkpoint inhibitor (ICI) treatment is unknown. OBJECTIVE: To assess practice patterns surrounding ICI treatment discontinuation at 2 years and to evaluate the association of duration of therapy with overall survival in patients who received fixed-duration ICI therapy for 2 years vs those who continued therapy beyond 2 years. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, population-based cohort study included adult patients in a clinical database diagnosed with advanced NSCLC from 2016 to 2020, who received frontline immunotherapy-based treatment. The data cutoff was August 31, 2022; data analysis was conducted from October 2022 to January 2023. EXPOSURES: Treatment discontinuation at 2 years (between 700 and 760 days, fixed duration) vs continued treatment beyond 2 years (greater than 760 days, indefinite duration). MAIN OUTCOMES AND MEASURES: Overall survival from 760 days was analyzed using Kaplan-Meier methods. Multivariable Cox regression that adjusted for patient-specific and cancer-specific factors was used to compare survival beyond 760 days between the fixed-duration group and the indefinite-duration group. RESULTS: Of 1091 patients in the analytic cohort who were still on ICI treatment at 2 years after exclusion criteria for death and progression were applied, 113 patients (median [IQR] age, 69 [62-75] years; 62 [54.9%] female; 86 [76.1%] White) were in the fixed-duration group, and 593 patients (median [IQR] age, 69 [62-76] years; 282 [47.6%] female; 414 [69.8%] White) were in the indefinite-duration group. Patients in the fixed-duration group were more likely to have a history of smoking (99% vs 93%; P = .01) and be treated at an academic center (22% vs 11%; P = .001). Two-year overall survival from 760 days was 79% (95% CI, 66%-87%) in the fixed-duration group and 81% (95% CI, 77%-85%) in the indefinite-duration group. There was no statistically significant difference in overall survival between patients in the fixed-duration and indefinite-duration groups, either on univariate (hazard ratio [HR] 1.26; 95% CI, 0.77-2.08; P = .36) or multivariable (HR 1.33; 95% CI, 0.78-2.25; P = .29) Cox regression. Approximately 1 in 5 patients discontinued immunotherapy at 2 years in the absence of progression. CONCLUSIONS AND RELEVANCE: In a retrospective clinical cohort of patients with advanced NSCLC who were treated with immunotherapy and were progression-free at 2 years, approximately only 1 in 5 discontinued treatment. The lack of statistically significant overall survival advantage for the indefinite-duration cohort on adjusted analysis provides reassurance to patients and clinicians who wish to discontinue immunotherapy at 2 years.
引用
- Sun L, Bleiberg B, Hwang WT, et al. Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2023. PMID: 37270700. doi:10.1001/jamaoncol.2023.1891
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。